We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$849M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+26.72%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$849M
AUM Growth
+$158M
(+23%)
Cap. Flow
+$88.5M
Cap. Flow
% of AUM
10.43%
Top 10 Holdings %
Top 10 Hldgs %
48.96%
Holding
87
New
21
Increased
16
Reduced
27
Closed
18
Top Buys
| 1 |
ZBIO
Zenas BioPharma
ZBIO
|
+$25.5M |
| 2 |
Monte Rosa Therapeutics
GLUE
|
+$18.6M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$16.9M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
+$16.5M |
| 5 |
Immunome
IMNM
|
+$16.1M |
Top Sells
| 1 |
ABVX
Abivax
ABVX
|
+$14.2M |
| 2 |
CG Oncology
CGON
|
+$11M |
| 3 |
Viridian Therapeutics
VRDN
|
+$10.8M |
| 4 |
Pfizer
PFE
|
+$10.4M |
| 5 |
Avalo Therapeutics
AVTX
|
+$9.52M |
Sector Composition
| 1 | Healthcare | 98.55% |
| 2 | Financials | 1.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KALV
1
DELISTED
KalVista Pharmaceuticals
KALV
| $57.9M | 6.82% |
2,876,407
+449,289
| +19% | +$7.24M |
|
2
Dianthus Therapeutics
DNTH
$5.54B
| $54.9M | 6.47% |
654,746
-95,390
| -13% | -$5.52M |
|
3
Cogent Biosciences
COGT
$6.58B
| $50.6M | 5.96% |
1,314,189
+68,935
| +6% | +$2.55M |
|
4
Celcuity
CELC
$5.42B
| $40.9M | 4.81% |
357,903
-17,229
| -5% | -$1.88M |
|
|
5
Immunome
IMNM
$2.56B
| $40.5M | 4.77% |
1,850,278
+724,068
| +64% | +$16.1M |
|
6
Kodiak Sciences
KOD
$2.71B
| $37.8M | 4.46% |
991,930
-31,192
| -3% | -$806K |
|
7
Nuvalent
NUVL
$9.81B
| $36.4M | 4.28% |
354,914
+43,484
| +14% | +$4.43M |
|
|
ABVX
8
Abivax
ABVX
$11.8B
| $33.7M | 3.97% |
302,530
-119,663
| -28% | -$14.2M |
|
|
9
Monte Rosa Therapeutics
GLUE
$1.98B
| $32.9M | 3.88% |
2,002,040
+972,974
| +95% | +$18.6M |
|
10
Erasca
ERAS
$6.06B
| $30M | 3.53% |
1,851,812
+534,228
| +41% | +$6.31M |
|
|
11
Ascendis Pharma A/S
ASND
$17.4B
| $28.5M | 3.36% |
124,658
+75,430
| +153% | +$16.9M |
|
12
UroGen Pharma
URGN
$1.91B
| $27M | 3.18% |
1,503,045
-235,776
| -14% | -$4.73M |
|
|
13
Rhythm Pharmaceuticals
RYTM
$7.54B
| $26.6M | 3.14% |
306,000
+170,050
| +125% | +$16.5M |
|
14
Praxis Precision Medicines
PRAX
$9.14B
| $23.1M | 2.72% |
71,552
-10,913
| -13% | -$3.38M |
|
|
ZBIO
15
Zenas BioPharma
ZBIO
$1.82B
| $22.2M | 2.62% |
+1,135,935
| New | +$25.5M |
|
16
Syndax Pharmaceuticals
SNDX
$2.14B
| $20.8M | 2.45% |
888,987
+246,088
| +38% | +$5.35M |
|
|
CNTA
17
DELISTED
Centessa Pharmaceuticals
CNTA
| $18.5M | 2.18% |
466,345
+8,142
| +2% | +$208K |
|
18
Scholar Rock
SRRK
$6.44B
| $16.7M | 1.97% |
+339,613
| New | +$15.2M |
|
19
Alkermes
ALKS
$8.6B
| $16.3M | 1.92% |
+460,314
| New | +$14.3M |
|
20
Oric Pharmaceuticals
ORIC
$1.09B
| $13.9M | 1.64% |
1,100,010
-16,594
| -1% | -$188K |
|
21
Disc Medicine
IRON
$2.87B
| $12.5M | 1.48% |
+196,028
| New | +$13.6M |
|
|
HLXC
22
Helix Acquisition Corp III
HLXC
$227M
| $12.3M | 1.45% |
+1,208,986
| New | +$12.4M |
|
23
Xenon Pharmaceuticals
XENE
$6.51B
| $11.5M | 1.36% |
+197,759
| New | +$9.11M |
|
|
24
CG Oncology
CGON
$6.33B
| $11.3M | 1.33% |
166,349
-194,809
| -54% | -$11M |
|
25
Immunovant
IMVT
$7.96B
| $10.3M | 1.21% |
+414,236
| New | +$10.7M |
|
Similar funds
BOTOTLSJU
EFG
LA
EPIMS
CFP
USAA
OMC
AIA